The 2025 Menopause Hormone-Therapy Label Reset: Which Warnings Went, Which Stayed, and Why

In November 2025 the U.S. Food and Drug Administration moved to remove the boxed warning from menopausal hormone therapy products. The change strikes the statements about cardiovascular disease, breast cancer, and probable dementia from the box that sits at the top of the prescribing information, and it keeps the boxed warning about endometrial cancer for systemic estrogen-alone products used by women who still have a uterus. The cardiovascular and breast cancer information does not vanish; it moves to other sections of the label rather than the boxed warning. A label change of this kind describes what the printed document legally says. It is not a recommendation to start therapy, an endorsement of any product, or a declaration that hormone therapy is now free of risk.

This article is educational and is not medical advice.

What a boxed warning is, and what removing one means

A boxed warning, often called a black box warning, is the most prominent safety statement the FDA can require on a prescription drug. It is reserved for risks the agency considers serious enough to flag before any other text. Because it is so visible, it also shapes how clinicians and patients perceive a whole drug class, sometimes beyond what the underlying data support.

Removing text from that box does not delete the underlying evidence. According to the FDA's own description of the action, risk information about cardiovascular disease and breast cancer is being retained in the labeling, just outside the boxed warning. The practical question the agency addressed was placement and emphasis: whether a single, uniform box at the top of every estrogen product still reflected what the studies actually showed across different ages, formulations, and routes of administration.

Which warnings went, and which stayed

The FDA's November 2025 action, described in its press materials and in the accompanying Department of Health and Human Services fact sheet, targeted the boxed warning across menopausal hormone therapy products, including systemic formulations and low-dose vaginal preparations. The risk statements removed from the box concern cardiovascular disease, breast cancer, and probable dementia.

One boxed warning was deliberately left in place. The agency did not seek to remove the endometrial cancer warning for systemic estrogen-alone products in women with a uterus. That distinction reflects a well-established mechanism: unopposed estrogen can stimulate the uterine lining, which is why estrogen-alone regimens are generally not used without a progestogen in women who have not had a hysterectomy. Keeping that specific warning while relocating the others is the clearest signal that the reset was selective rather than wholesale.

Why the box was there in the first place

The boxed warning traces to interpretations of the Women's Health Initiative (WHI), the large randomized program whose first results appeared in the early 2000s. Those early findings, drawn substantially from one systemic formulation studied largely in women well past the menopausal transition, were read as showing increased risks of cardiovascular events, breast cancer, and cognitive harm. The response was a broad class-wide warning.

Longer follow-up complicated that first reading. A peer-reviewed analysis of the 2025 action, published in the National Library of Medicine's PubMed Central, summarizes extended WHI data indicating that risk estimates are markedly lower when therapy is initiated in women younger than 60 or within about 10 years of menopause onset. In that population the analysis reports no statistically significant increase in coronary heart disease and describes reductions in all-cause mortality and osteoporotic fractures. This age-and-timing pattern is often called the timing hypothesis. It is a description of what the trial data show in a defined group; it is not a promise about any individual's outcome.

Systemic versus low-dose vaginal estrogen

A recurring point across the FDA materials is that not all estrogen products carry the same systemic exposure. Low-dose vaginal estrogen, used for local genitourinary symptoms, is absorbed into the bloodstream only in small amounts. The peer-reviewed analysis cites a Cochrane review of randomized trials finding no increased risk of endometrial or breast cancer with these local preparations. The concern raised for years was that applying a systemic-therapy box to a locally acting product may have discouraged use out of proportion to the evidence. The relabeling addresses that mismatch directly.

What the change is not

The boundaries here matter, because a headline about a warning being lifted can be misread as a green light. Removing risk language from the box does not change the case-by-case nature of the decision. Systemic estrogen still carries potential risks in certain individuals, and medical history, comorbidities, symptoms, and preferences all bear on the choice. Contraindications that applied before the relabeling, such as a personal history of hormone-sensitive cancer, prior blood clots, or certain cardiovascular events, continue to apply, and they are matters for an individualized conversation with a clinician.

In regulatory terms, moving risk language out of the box does not lower the evidentiary bar for a given person. The same variables that governed a hormone therapy decision before November 2025 still govern it: age, time since menopause, symptom burden, and individual medical background. The label reset changes the framing a reader encounters first. It does not resolve the underlying tradeoffs that the box once condensed into a single alarm.

How to read the news carefully

For anyone following this story, three distinctions help. First, separate the boxed warning from the rest of the label; text left the box but not the document. Second, separate systemic from local products, because their exposure and risk profiles differ. Third, separate a population-level trial signal from an individual prediction, which is where a clinician's judgment does the work a label cannot.